The primary outcome was an evaluated acute arterial thrombosis composition, venous thromboembolism, extracorporeal membrane oxygenation, or all-cause mortality for 30 days after enrollment. The pre-specified primary cohort consisted of patients who received at least 1 dose of the study drug, were not excluded, and did not withdraw consent. The mean follow-up time was 30 (9-30) […]